im21 car-t cell
Cell therapyexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 10, 2018 (NCT03711864)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- BCMAImmunity, passive
BCMA immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05478343 | Early Phase 1 (Phase 1) | May 6, 2021 | Beijing Immunochina Medical Science & Technology Co., Ltd., China Medical University |
| NCT04537442 | Phase 1 | Sep 3, 2020 | Beijing Immunochina Medical Science & Technology Co., Ltd., Peking University |
| NCT03711864 | Phase 1 | Oct 10, 2018 | Beijing Immunochina Medical Science & Technology Co., Ltd., Chinese Academy of Medical Sciences |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing Immunochina Medical Science & Technology Co., Ltd. | For profit | 3 | 2 | 1 | 2018 |
| China Medical University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1